- Home
- KAVL vs ENSC Comparison
KAVL vs ENSC Comparison
Compare KAVL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- ENSC
- Stock Information
- Founded
- KAVL 1998
- ENSC 2003
- Country
- KAVL United States
- ENSC United States
- Employees
- KAVL N/A
- ENSC N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- ENSC Health Care
- Exchange
- KAVL Nasdaq
- ENSC Nasdaq
- Market Cap
- KAVL 7.9M
- ENSC 4.9M
- IPO Year
- KAVL N/A
- ENSC N/A
- Fundamental
- Price
- KAVL $0.48
- ENSC $2.31
- Analyst Decision
- KAVL
- ENSC
- Analyst Count
- KAVL 0
- ENSC 0
- Target Price
- KAVL N/A
- ENSC N/A
- AVG Volume (30 Days)
- KAVL 31.9K
- ENSC 64.4K
- Earning Date
- KAVL 07-15-2025
- ENSC 08-13-2025
- Dividend Yield
- KAVL N/A
- ENSC N/A
- EPS Growth
- KAVL N/A
- ENSC N/A
- EPS
- KAVL N/A
- ENSC N/A
- Revenue
- KAVL $1,698,426.00
- ENSC $6,224,081.00
- Revenue This Year
- KAVL N/A
- ENSC N/A
- Revenue Next Year
- KAVL N/A
- ENSC $1,381.48
- P/E Ratio
- KAVL N/A
- ENSC N/A
- Revenue Growth
- KAVL N/A
- ENSC 256.35
- 52 Week Low
- KAVL $0.45
- ENSC $1.62
- 52 Week High
- KAVL $1.95
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- KAVL 32.59
- ENSC 53.77
- Support Level
- KAVL $0.45
- ENSC $2.15
- Resistance Level
- KAVL $0.54
- ENSC $2.34
- Average True Range (ATR)
- KAVL 0.04
- ENSC 0.10
- MACD
- KAVL -0.01
- ENSC 0.03
- Stochastic Oscillator
- KAVL 19.23
- ENSC 90.63
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.